AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
10.33
-0.26 (-2.46%)
Feb 21, 2025, 4:00 PM EST - Market closed
AngioDynamics Revenue
AngioDynamics had revenue of $72.85M in the quarter ending November 30, 2024, a decrease of -7.88%. This brings the company's revenue in the last twelve months to $286.50M, down -13.06% year-over-year. In the fiscal year ending May 31, 2024, AngioDynamics had annual revenue of $303.91M, down -10.28%.
Revenue (ttm)
$286.50M
Revenue Growth
-13.06%
P/S Ratio
1.46
Revenue / Employee
$383,019
Employees
748
Market Cap
418.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
May 31, 2024 | 303.91M | -34.84M | -10.28% |
May 31, 2023 | 338.75M | 22.53M | 7.13% |
May 31, 2022 | 316.22M | 25.21M | 8.66% |
May 31, 2021 | 291.01M | 26.85M | 10.17% |
May 31, 2020 | 264.16M | -6.48M | -2.39% |
May 31, 2019 | Pro | Pro | Pro |
May 31, 2018 | Pro | Pro | Pro |
May 31, 2017 | Pro | Pro | Pro |
May 31, 2016 | Pro | Pro | Pro |
May 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ANGO News
- 23 days ago - AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia - Business Wire
- 5 weeks ago - AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares - Seeking Alpha
- 5 weeks ago - AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI - Business Wire
- 6 weeks ago - AngioDynamics: A Surgical Approach To Market Growth - Seeking Alpha
- 6 weeks ago - AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results - Business Wire
- 6 weeks ago - AngioDynamics to Present at the J.P. Morgan Healthcare Conference - Business Wire
- 6 weeks ago - AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System - Business Wire